财中社12月2日电康哲药业(00867)发布公告,宣布其全资附属公司与杭州新元素药业有限公司签订了关于治疗痛风及高尿酸血症的1类新药ABP-671的独家商业化协议。根据协议,公司获得了该产品在中国大陆、香港特别行政区及澳门特别行政区的独家商业化权利,合作期限为十年,且在特定条件下可自动续期十年。ABP-671是一种用于治疗痛风及高尿酸血症的创新药物,目前正在进行2b/3期临床试验。初步数据显示,该...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.